These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 16426102

  • 1. Real-life switching strategies with second-generation antipsychotics.
    Correll CU.
    J Clin Psychiatry; 2006 Jan; 67(1):160-1. PubMed ID: 16426102
    [No Abstract] [Full Text] [Related]

  • 2. Optimizing atypical antipsychotic treatment strategies in the elderly.
    Katz IR.
    J Am Geriatr Soc; 2004 Dec; 52(12 Suppl):S272-7. PubMed ID: 15541168
    [No Abstract] [Full Text] [Related]

  • 3. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE.
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract] [Full Text] [Related]

  • 4. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM, Perry PJ.
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract] [Full Text] [Related]

  • 5. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
    Citrome L, Volavka J.
    Postgrad Med; 2004 Oct; 116(4):49-51, 55-9, 63. PubMed ID: 15510593
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Switching antipsychotic medications: not enough, too often, or just right?
    Weiden PJ.
    Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ, Johnson EG, Johnson HE, Ensom MHH.
    Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
    Lorenz RA, Jackson CW, Saitz M.
    Pharmacotherapy; 2010 Sep; 30(9):942-51. PubMed ID: 20795849
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
    McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A.
    J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.